Branch Retinal Vein Occlusion

• FDA approval · 2022-06-09
  FDA Approved: BYOOVIZ — Supplemental Application (BIOGEN INC.)

  The FDA approved a supplemental application for BYOOVIZ (ranibizumab-nuna) from Biogen, authorizing its use as a biosimilar to ranibizumab.

• FDA approval · 2019-08-12
  FDA Approved: EYLEA — Supplemental Application (Regeneron Pharmaceuticals, Inc.)

  The FDA approved Regeneron's supplemental application for EYLEA (aflibercept), updating its labeling to reflect an expanded or modified indi…

• FDA approval · 2018-08-16
  FDA Approved: EYLEA — Supplemental Application (Regeneron Pharmaceuticals, Inc.)

  FDA has approved a supplemental application for EYLEA (aflibercept) from Regeneron Pharmaceuticals, Inc. The approval indicates the suppleme…

• FDA approval · 2012-02-24
  FDA Approved: OZURDEX — Supplemental Application (Allergan, Inc.)

  FDA approved a supplemental application for OZURDEX (dexamethasone) from Allergan, Inc.